IMP-27, a unique metallo-β-lactamase identified in geographically distinct isolates of Proteus mirabilis

Nyssa Dixon, Randal C. Fowler, A. Yoshizumi, Tsukasa Horiyama, Y. Ishii, Lucas Harrison, Chelsie N. Geyer, Ellen Smith Moland, Kenneth Thomson, Nancy D. Hanson

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

A novel metallo-β-lactamase gene, blaIMP-27, was identified in unrelated Proteus mirabilis isolates from two geographically distinct locations in the United States. Both isolates harbor blaIMP-27 as part of the first gene cassette in a class 2 integron. Antimicrobial susceptibility testing indicated susceptibility to aztreonam, piperacillin-tazobactam, and ceftazidime but resistance to ertapenem. However, hydrolysis assays indicated that ceftazidime was a substrate for IMP-27.

Original languageEnglish (US)
Pages (from-to)6418-6421
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number10
DOIs
StatePublished - Oct 1 2016

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Dixon, N., Fowler, R. C., Yoshizumi, A., Horiyama, T., Ishii, Y., Harrison, L., Geyer, C. N., Moland, E. S., Thomson, K., & Hanson, N. D. (2016). IMP-27, a unique metallo-β-lactamase identified in geographically distinct isolates of Proteus mirabilis. Antimicrobial Agents and Chemotherapy, 60(10), 6418-6421. https://doi.org/10.1128/AAC.02945-15